Basic Investigations EXPRESSION OF GAP JUNCTION PROTEIN Cx43 IN CULTURED HUMAN NORMAL AND MALIGNANT LUNG CELLS

ＢａｓｉｃＩｎｖｅｓｔｉｇａｔｉｏｎｓＥＸＰＲＥＳＳＩＯＮＯＦＧＡＰＪＵＮＣＴＩＯＮＰＲＯＴＥＩＮＣｘ４３ＩＮＣＵＬＴＵＲＥＤＨＵＭＡＮＮＯＲＭＡＬＡＮＤＭＡＬＩＧＮＡＮＴＬＵＮＧＣＥＬＬＳＺｈａｎｇＺｈｉｑｉａｎ；张志谦；ＬｉｎＺｈｏｎｇｘｉａｎｇ...     

PRINCIPLES AND APPLICATIONS OF MOLECULAR EPIDEMIOLOGY AND STUDIES OF HUMAN PROSTATIC CARCINOMA

ＰＲＩＮＣＩＰＬＥＳＡＮＤＡＰＰＬＩＣＡＴＩＯＮＳＯＦＭＯＬＥＣＵＬＡＲＥＰＩＤＥＭＩＯＬＯＧＹＡＮＤＳＴＵＤＩＥＳＯＦＨＵＭＡＮＰＲＯＳＴＡＴＩＣＣＡＲＣＩＮＯＭＡＴｚｅ－ｃｈｅｎＨｓｉｅｈ；ＣｈｕｎｙｕｎｇＮｇａｎｄＪｏｓｅｐｈＭ．Ｗｕ（Ｄｅｐｔ...     

Special Reports and Review ONCOGENES AND CELL IMMUNOGENITY：v－H－ras SUPPRESSING MHC CLASS I EXPRESSION IN MOUSE FIBROBLAST

ＳｐｅｃｉａｌＲｅｐｏｒｔｓａｎｄＲｅｖｉｅｗＯＮＣＯＧＥＮＥＳＡＮＤＣＥＬＬＩＭＭＵＮＯＧＥＮＩＴＹ：ｖ－Ｈ－ｒａｓＳＵＰＰＲＥＳＳＩＮＧＭＨＣＣＬＡＳＳＩＥＸＰＲＥＳＳＩＯＮＩＮＭＯＵＳＥＦＩＢＲＯＢＬＡＳＴＬｕＹｏｕｙｏｎｇ；吕有勇；Ｓｈｒａｇ...     

THE TECHNIQUE OF THE NORMOTHERMIC AND HYPOTHERMIC TOTAL HEPATIC VASCULAR EXCLUSION FOR RESECTION OF THE LIVER TUMORS

ＴＨＥＴＥＣＨＮＩＱＵＥＯＦＴＨＥＮＯＲＭＯＴＨＥＲＭＩＣＡＮＤＨＹＰＯＴＨＥＲＭＩＣＴＯＴＡＬＨＥＰＡＴＩＣＶＡＳＣＵＬＡＲＥＸＣＬＵＳＩＯＮＦＯＲＲＥＳＥＣＴＩＯＮＯＦＴＨＥＬＩＶＥＲＴＵＭＯＲＳＨｕａｎｇＪｉｅｆｕ黄洁夫ＬｉＧｕｉｓｈｅｎｇ李桂...     

CLINICOPATHOLOGIC FEATURES AND DIAGNOSISOF COMBINED HEPATOCELLULAR ANDCHOLANGIOCARCINOMA

ＣＬＩＮＩＣＯＰＡＴＨＯＬＯＧＩＣＦＥＡＴＵＲＥＳＡＮＤＤＩＡＧＮＯＳＩＳＯＦＣＯＭＢＩＮＥＤＨＥＰＡＴＯＣＥＬＬＵＬＡＲＡＮＤＣＨＯＬＡＮＧＩＯＣＡＲＣＩＮＯＭＡＬｕＪｉａｎｐｉｎｇ路建平；ＣａｉＷｅｉｍｉｎ蔡为民；ＨａｙａｓｈｉＫｅｉｋｉ１林肇辉...     

THE THERMOSENSITIVITY OF HUMAN GINGIVAL SQUAMOUS CARCINOMA Ca9－22 CELLS WITH ONCOGENE erbB－1／EGFR

ＴＨＥＴＨＥＲＭＯＳＥＮＳＩＴＩＶＩＴＹＯＦＨＵＭＡＮＧＩＮＧＩＶＡＬＳＱＵＡＭＯＵＳＣＡＲＣＩＮＯＭＡＣａ９－２２ＣＥＬＬＳＷＩＴＨＯＮＣＯＧＥＮＥｅｒｂＢ－１／ＥＧＦＲＺｈａｎｇＳｈａｎｗｅｎ;Ｅ．Ｋａｎｏ;Ｙ．Ｙａｍａｚａｋｉ;Ｓ．Ｈａｙａｓｈ...     

INVESTIGATION OF BLOOD SUPPLY OF BRONCHOGENIC CARCINOMA DERIVING FROM PULMONARY ARTERY

ＩＮＶＥＳＴＩＧＡＴＩＯＮＯＦＢＬＯＯＤＳＵＰＰＬＹＯＦＢＲＯＮＣＨＯＧＥＮＩＣＣＡＲＣＩＮＯＭＡＤＥＲＩＶＩＮＧＦＲＯＭＰＵＬＭＯＮＡＲＹＡＲＴＥＲＹＺｈｅｎｇＲｕｈｅｎｇ郑如恒ＤｏｎｇＹｏｎｇｈｕａ董永华ＺｈｏｕＫａｎｇｒｏｎｇ周康荣（Ｄｅｐａｒ...     

LOSS OF HETEROZYGOSITY INVOLVING THE APC TUMOR SUPPRESSOR GENE IN HUMAN COLORECTAL CARCINOMA

ＬＯＳＳＯＦＨＥＴＥＲＯＺＹＧＯＳＩＴＹＩＮＶＯＬＶＩＮＧＴＨＥＡＰＣＴＵＭＯＲＳＵＰＰＲＥＳＳＯＲＧＥＮＥＩＮＨＵＭＡＮＣＯＬＯＲＥＣＴＡＬＣＡＲＣＩＮＯＭＡ￥ＸｕＷｅｎｈｕａｉ；徐文怀；ＹａｎｇＤｉｎｇｃｈｅｎｇ；杨定成（Ｄｅｐａｒｔｍｅｎｔｏｆ...     

STUDIES ON THE GAP JUNCTIONAL INTERCELLULARCOMMUNICATION OF HUMAN NASOPHARYNGEALCARCINOMA CELLS AND THE EFFECT OF RII

ＳＴＵＤＩＥＳＯＮＴＨＥＧＡＰＪＵＮＣＴＩＯＮＡＬＩＮＴＥＲＣＥＬＬＵＬＡＲＣＯＭＭＵＮＩＣＡＴＩＯＮＯＦＨＵＭＡＮＮＡＳＯＰＨＡＲＹＮＧＥＡＬＣＡＲＣＩＮＯＭＡ　ＣＥＬＬＳＡＮＤＴＨＥＥＦＦＥＣＴＯＦＲＩＩＨａｎＬｉｑｕｎ韩立群；ＧａｏＪｉｎ高进；...     

IMAGING FINDINGS OF MALIGNANT FIBROUS HISTOCYTOMA (MFH) IN THE LUNG

ＩＭＡＧＩＮＧＦＩＮＤＩＮＧＳＯＦＭＡＬＩＧＮＡＮＴＦＩＢＲＯＵＳＨＩＳＴＯＣＹＴＯＭＡ（ＭＦＨ）ＩＮＴＨＥＬＵＮＧＤａｉＪｉｎｇｒｕｉ戴景蕊ＪｉａｎｇＬｉｍｉｎｇ蒋力明ＺｈａｎｇＹｕ张宇ＺｈａｎｇＸｉａｏｂｏ张晓波ＣａｎｃｅｒＩｎｓｔｉｔｕｔｅ（Ｈ...     

Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion

Chemotherapy with bronchial artery infusion (BAI) was given to 34 patients with primary lung cancer. Treatment regimens usually employed cis-diammine-dichloroplatinum (CDDP) plus peplomycin for squamous cell carcinoma, and CDDP plus vindesine for adenocarcinoma. The provisional therapeutic effects were evaluated roentgenographically with reference to histological type, T factor and degree of vascularization. Out of 10 cases of squamous cell carcinoma, 7 cases (70%) showed tumor regression greater than 50%, in contrast to 4 of 17 cases (23.5%) of adenocarcinoma. The effects in cases of squamous cell carcinoma were correlated with tumor vascularity. Twenty-two surgically treated cases were examined for the histological effects of BAI. Five of 6 cases (83.3%) of squamous cell carcinoma showed IIb effects by Shimosato's criteria. These results showed that the therapeutic effect of BAI was excellent in cases of squamous cell carcinoma in comparison with cases of adenocarcinoma. Serious side effects including esophago-bronchial fistula, massive hemoptysis and esophageal ulcer were observed in 4 cases.     

P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples

BACKGROUND:

Bevacizumab in combination with carboplatin and paclitaxel improves overall response and survival in patients with advanced or recurrent nonsmall cell lung carcinoma. However, this drug is not recommended in patients with squamous cell carcinoma or neoplasms with a dominant squamous component. Therefore, identification of squamous cell differentiation has therapeutic implications. In many instances, cytology is the diagnostic tool of choice; however, routine cytomorphology is limited in classification of nonsmall cell carcinomas into squamous and nonsquamous subtypes. The aim of this study was to identify the value of p63 immunocytochemical analysis in this distinction.

METHODS:

Review of cytology records identified 51 consecutive pulmonary specimens (16 fine needle aspiration samples, 15 washes, 12 brushes, and 8 lavages) with the diagnosis of nonsmall cell lung carcinoma (9 carcinomas with squamous differentiation and 42 carcinomas without squamous differentiation). Histologically, they all proved to be nonsmall cell carcinomas, 26 with squamous differentiation and 25 without squamous differentiation. p63 immunocytochemical stain was performed on archival alcohol‐fixed Papanicolaou‐stained cytology slides using standard immunocytochemical methods.

RESULTS:

Twenty‐three (88 %) of the 26 histologically proven squamous cell carcinomas were positive for p63 on cytologic smears. By using p63 immunocytochemistry, the authors detected 14 carcinomas with squamous differentiation not identified by cytomorphology. Smears from all histologically proven carcinomas with squamous differentiation were positive for p63. Sensitivity of cytology for the detection of nonsmall cell carcinoma of lung with squamous differentiation increased from 35% to 88% using p63 immunocytochemistry (P = .001; McNemar test). The squamous component in 4 carcinomas was detected only in cytologic and not in corresponding histologic samples when subsequent p63 immunostaining was performed.

CONCLUSIONS:

The authors concluded that p63 is a useful marker for the detection of nonsmall cell carcinomas of lung with squamous differentiation when used in cytologic pulmonary samples. p63 immunocytochemistry significantly increases the sensitivity for the identification of lung neoplasms with squamous differentiation from 35% to 88% (P = .001). Therefore, p63 immunocytochemistry may be used in pulmonary cytologic samples of nonsmall cell carcinomas to identify squamous differentiation and to improve therapeutic selection of patients with lung cancer. Cancer (Cancer Cytopathol) 2009. © 2009 American Cancer Society.     

Leptomeningeal Carcinomatosis after Major Remission to Taxane-based Front-line Therapy in Patients with Advanced Breast Cancer

Aim: To determine the incidence of leptomeningeal carcinomatosis (LMC), as the first manifestation of systemic progression, in breast cancer patients after obtaining a major response (complete response, CR or >80% partial response, PR) to first-line taxane-based chemotherapy treated between 1996 and 2000 in our Medical Oncology Unit. Patients and methods: Patients with histologically proven breast cancer having either metastatic disease, or high-risk locoregional disease that were entered into treatment protocols with first-line taxane (paclitaxel or docetaxel) plus anthracyclines or mitoxantrone combinations and developed LMC as the first evidence of progression after major response (CR or >80% PR) were analyzed in the present study (n=155). Results: Seven patients with a median age of 54 (range: 40–70) years developed LMC as their first evidence of progression after taxane-based regimens with a median interval of 6 months (range: 2–18) from start of treatment to diagnosis of LMC. Five patients received intrathecal (i.t.) methotrexate treatment and whole brain radiotherapy (RT), while one patient received i.t. methotrexate and RT to lumbar spine. Two patients responded to treatment for LMC, while two achieved stable disease and three progressed. Two patients had elevated cerebrospinal fluid tumor markers (more than serum marker levels) that proved useful in monitoring response to treatment. Median survival after LMC was 3.6 months (range: 1–31+) and correlated positively to the interval from the initiation of taxane-based therapy to LMC (r=0.84, P=0.019). Seven out of 86 responders (8.1%; 95% confidence interval, 2.4–13.9) developed LMC as the first sign of progression after a major response to first-line chemotherapy. Conclusions: LMC after a major response to front-line taxane-based regimens represents a grave disease manifestation and its incidence appears increased when compared in retrospect to non-taxane-treated patients. Prospective evaluation of the incidence of LMC after taxane versus non-taxane-based treatment from large randomized multi-institutional trials is warranted and identification of potential prognostic factors might help identify patients requiring appropriate prophylactic therapy.     

The clinicopathological effects of infusion of cis-platinum into the bronchial artery on lung cancer

Ten patients with histologically and/or cytologically confirmed lung cancer were treated with cis-platinum (CDDP) infused into the bronchial artery (BAI). Radiological findings on chest X-rays taken two weeks after BAI were evaluated according to Takeuchi's criteria. The radiological results were judged to be quite effective in one case of squamous cell carcinoma, with more than 50% shrinkage of the tumor shadow, and to be effective in nine others, with more than 20% shrinkage. As for the histological effects, grade III in one case of squamous cell carcinoma and grade IIa in two cases of adenocarcinoma and one of large cell carcinoma were obtained by Shimosato's criteria. In conclusion, BAI with CDDP was sufficiently useful as a chemotherapeutic modality for lung cancer, especially squamous cell carcinoma, because higher local dosage of CDDP can be delivered without systemic toxicity.     

Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy for inoperable squamous cell carcinoma of the esophagus potentially followed by surgery

Twenty-four previously untreated patients with primary inoperable squamous cell carcinoma of the esophagus showing no evidence of hematogenous metastasis were treated with concurrent chemotherapy and radiation therapy (CRT) followed by surgical resection if possible. The chemotherapy regimen consisted of 5-fluorouracil 750 mg/m² on days 1–4 and 21–24, and cisplatin 70 mg/m² on days 1 and 21. Radiation therapy was administered over days 1–26 (200 cGy/day five times per week with an initial planned dose of 40 Gy). Five patients (8%) showed complete response (CR), 14 patients (58%) had partial response (PR), and 19 had good local control (CR 2, PR 17). Eleven cases (48%) underwent esophageal resection with no operative mortality. Curative resection was accomplished in eight cases (35%). Toxicities observed in CRT were leukopenia (grades 3 and 4) 38%, nausea and vomiting (grades 2 and 3) 67%, esophagitis 42%, and fever 42%. The median survival time (MST) for 11 neoadjuvant cases was 349 days (P < 0.05) compared to 212 days for palliative treatment (six cases) and 126 days for no treatment (six cases) after CRT. The MST of eight patients who received curative resection had not been reached after a 17-month median follow-up time. Concurrent chemotherapy with 5-fluorouracil plus cisplatin and radiation proved to be a safe regimen yielding a satisfactory response and minimal toxicity in this particular group of patients. Extensive surgery was thus determined to be feasible after CRT and to contribute to prolonging survival. © 1995 Wiley-Liss, Inc.     

支气管动脉灌注化疗治疗肺癌的临床研究

目的　探讨支气管动脉灌注化疗 (BAI)对中晚期肺癌的疗效及影响因素。方法　对 45例中晚期肺癌进行BAI治疗 ,与同期接受全身化疗的 40例中晚期肺癌进行比较。结果　除开 1例大细胞肺癌 ,BAI组完全缓解 (CR) 15例 ( 3 4.1% ) ,部分缓解 (PR) 18例 ( 4 0 .9% ) ,缓解 (CR +PR) 3 3例 ,缓解率 75 .0 % ,与全身化疗之间的疗效 ( 5 0 .0 % )有显著性差异 ,前者优于后者 (P <0 .0 5 ) ,前者毒副反应亦少于后者 (P <0 .0 5 ) ,但BAI组有 1例灌注后截瘫。在BAI组中 ,小细胞未分化癌、鳞癌、腺癌的缓解率分别为 94.5 %、66.6%、40 .0 %。BAI组鳞癌和腺癌的缓解率显著高于全身化疗组 (P <0 .0 5 )。结论　BAI的疗效优于全身静脉化疗 ,且毒副反应低。鳞癌首选BAI治疗 ,小细胞未分化癌以全身化疗为基础 ,辅助应用BAI治疗 ,腺癌可先行BAI治疗 ,配合全身化疗或放疗     

含羟基喜树碱联合方案治疗中晚期非小细胞肺癌

目的 :观察含羟基喜树碱 (HCPT)联合方案治疗中晚期非小细胞肺癌 (NSCLC)患者的客观疗效及毒副作用。方法 :4 6例中晚期非小细胞肺癌患者为治疗组 ,应用含羟基喜树碱方案化疗 ,其中 2 5例肺腺癌患者接受HFAP方案 ,2 1例肺鳞癌患者接受HCAP方案 ,4周为一周期 ,2周期为一疗程 ;以同期住院的未用HCPT联合化疗的同类患者 4 2例作为对照组 ,其剂量、周期、疗程与治疗组相同 ,但不用HCPT。结果 :治疗组 4 3例患者完成一疗程治疗 ,肺腺癌有效率为 5 6 % ,CR 2例 ,PR 12例 ;肺鳞癌有效率为 5 5 5 % ,CR为 0 ,PR 10例 ,总有效率 (CR +PR)为 5 5 8% ;对照组 4 2例均完成一疗程治疗 ,肺腺癌有效率为37 5 % ,CR 1例 ,PR 9例 ;肺鳞癌有效率为 33 3% ,PR 6例 ,有效率 35 7% ;两组间差异显著 (P <0 0 5 )。治疗组和对照组的毒副反应主要表现为食欲不振、脱发、恶心呕吐和白细胞及血小板减少 ,两组毒副反应发生率无显著性差异 (P >0 0 5 )。结论 :羟基喜树碱联合化疗治疗中晚期非小细胞肺癌疗效确切 ,副作用可耐受 ,该药是治疗非小细胞肺癌较为有效的药物 ,值得进一步在临床中观察和研究。     

P73、ER、PR在食管癌及癌前病变中的表达及临床意义

Objective： To test the expression of mutant p73, p53, ER and PR proteins in the esophageal normal mucosa, hyperplasia, dysplasia and squamous cell carcinoma, and research the clinically pathological significance and the correlation, for the early diagnosis, prognostic measure and therapy in clinic. Methods： With Immunohistochemistry, it was examined to show these tumor markers＇ expression in different epithelial lesions of 40 esophageal squamous cell carcinomas, 14 dysplasias, 14 hyperplasias and 14 normal mucosas. Results： The expression of p73 was 55%, 21%, 0% and 0% in the esophageal carcinoma, dysplasia, hyperplasia and normal mucosa, respectively. The significant difference in expression of p73 （P〈0.001） was observed between the esophageal normal mucosia, hyperplasia, dysplasia and esophageal squamous cell carcinoma with Fisher＇s exact test. Difference in expression of p73 （P〈0.05） was observed between the esophageal squamous cell carcinoma and dysplasia with X^2 test. The expression of p73 showed non-correlation with the patient＇s age, sex, tumor＇s grade, lymph-node metastasis and invasive depth （P〉0.05）; Similarly, the expression of mutant p53 was 67.5%, 35.7%, 7% and 0%, respectively; In like manner, the expression of ER was 55%, 21.4%, 14.2% and 0%, respectively; The expression of PR was 57.5%,14.28%, 0% and 0%, respectively. The significant difference in expression of PR （P〈0.001） was observed with Fisher＇s exact test. Difference in expression of PR （P〈0.05） was observed between the esophageal squamous cell carcinoma and dysplasia with x2 test. The expression of PR （P〈0.05） was correlated with lymph-node metastasis, and showed non-correlation with the patient＇s age, sex, tumor＇s grade, and invasive depth （P〉0.05）. Moreover, over-expression of mutant p53 and p73 showed significant correlation with ER and PR protein＇s positive expression （P〈0.05）. Conclusion： P73 protein may become a new tumor＇s marker to diagnose esophageal squarnous celt carcinoma. Because the expression of p73 protein was closely correlated with ER and PR, they could be simultaneously examined to help to early diagnose, prognosticate and cure esophageal carcinoma.     

Prospective study with HEXA-CAF combination in ovarian carcinoma

Summary The value of combination chemotherapy with HEXA-CAF was analyzed in 31 patients with histologically documented epithelial ovarian cancer in advanced stages (minimal or gross disease). No patient had been previously treated with chemotherapy. Peritoneoscopy with diaphragmatic inspection, peritoneal cytology, lymphography, and chest X-ray were routinely used in staging and restaging the patients. Complete (CR) plus partial (PR) responses were obtained in 13/31 fully restaged patients (41.9%). CR was recorded in seven patients (22.5%) and PR in six patients (19.3%). Remission duration was significantly longer in patients who achieved CR (20 months) than in those who attained PR (9.5 months)(P<0.01). In all treated patients the median duration of survival was 16.5 months. Survival was significantly longer in patients with CR than in patients who did not achieve CR (P<0.05). Nevertheless, considering the rate of CR in patients with gross disease (20.6%), HEXA-CAF combination seems a useful but not yet ahopeful treatment for patients with advanced ovarian carcinoma.     

BAI及BAE术治疗老年中晚期肺癌的疗效观察

目的 观察支气管动脉灌注化疗(BAI)及化疗栓塞术(BAE)治疗老年中晚期肺癌患者的疗效.方法采用BAI及BAE术治疗老年中晚期肺癌患者,观察其近期疗效及毒副反应.结果32例患者中CR 2例,PR 15例,SD 7例,PD 8例,有效率为53.12%.结论采用BAI及BAE治疗老年中晚期肺癌疗效确切,且毒副反应能耐受.